This hasn't even hit the news feeds yet; wait until tomorrow when fund managers etc have had time to digest the news and put the slide rules over it. C'mon, a fully paid study paid for by the largest biotech company in the world, Amgen, who recently paid over 10 bill for another company in the same space? This is an overdue re-rating. Don't pity the buyers in the 9's. Not even the buyers in the 90's.
